EFALIZUMAB: 230 Adverse Event Reports & Safety Profile
Visibly Younger Skin in Weeks
Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.
230
Total FAERS Reports
73 (31.7%)
Deaths Reported
44
Hospitalizations
230
As Primary/Secondary Suspect
2
Life-Threatening
2
Disabilities
First Report: 2004 · Latest Report: 20211011
What Are the Most Common EFALIZUMAB Side Effects?
#1 Most Reported
Death
56 reports (24.3%)
#2 Most Reported
Psoriasis
55 reports (23.9%)
#3 Most Reported
Pruritus
35 reports (15.2%)
All EFALIZUMAB Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 56 | 24.4% | 56 | 2 |
| Psoriasis | 55 | 23.9% | 3 | 13 |
| Pruritus | 35 | 15.2% | 8 | 1 |
| Erythema | 28 | 12.2% | 4 | 0 |
| Drug ineffective | 26 | 11.3% | 3 | 6 |
| Pain | 25 | 10.9% | 10 | 1 |
| Decreased appetite | 24 | 10.4% | 0 | 0 |
| Hypersensitivity | 24 | 10.4% | 1 | 1 |
| Vomiting | 24 | 10.4% | 0 | 2 |
| Nausea | 23 | 10.0% | 1 | 0 |
| Condition aggravated | 22 | 9.6% | 0 | 8 |
| Myalgia | 22 | 9.6% | 0 | 0 |
| Fatigue | 20 | 8.7% | 0 | 0 |
| Skin exfoliation | 19 | 8.3% | 5 | 0 |
| Skin plaque | 12 | 5.2% | 6 | 0 |
| Haemorrhage | 11 | 4.8% | 3 | 0 |
| Weight decreased | 11 | 4.8% | 0 | 1 |
| Progressive multifocal leukoencephalopathy | 10 | 4.4% | 1 | 9 |
| Asthenia | 9 | 3.9% | 0 | 9 |
| Cachexia | 9 | 3.9% | 0 | 9 |
Who Reports EFALIZUMAB Side Effects? Age & Gender Data
Gender: 46.2% female, 53.8% male. Average age: 52.3 years. Most reports from: US. View detailed demographics →
Is EFALIZUMAB Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2004 | 2 | 0 | 1 |
| 2005 | 2 | 1 | 0 |
| 2006 | 7 | 1 | 6 |
| 2007 | 7 | 1 | 5 |
| 2008 | 3 | 3 | 0 |
| 2009 | 6 | 1 | 5 |
| 2010 | 3 | 0 | 1 |
| 2011 | 2 | 0 | 1 |
| 2012 | 4 | 3 | 4 |
| 2013 | 8 | 1 | 2 |
| 2014 | 3 | 0 | 2 |
| 2015 | 3 | 1 | 2 |
| 2016 | 9 | 0 | 1 |
| 2017 | 4 | 0 | 0 |
| 2018 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 0 |
| 2021 | 8 | 8 | 0 |
What Is EFALIZUMAB Used For?
| Indication | Reports |
|---|---|
| Psoriasis | 157 |
| Pustular psoriasis | 101 |
| Product used for unknown indication | 51 |
| Psoriatic arthropathy | 8 |
EFALIZUMAB vs Alternatives: Which Is Safer?
EFALIZUMAB vs EFANESOCTOCOG ALFA
EFALIZUMAB vs EFAVIRENZ
EFALIZUMAB vs EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL
EFALIZUMAB vs EFAVIRENZ\LAMIVUDINE\TENOFOVIR DISOPROXIL
EFALIZUMAB vs EFFEXOR
EFALIZUMAB vs EFFIENT
EFALIZUMAB vs EFGARTIGIMOD ALFA
EFALIZUMAB vs EFGARTIGIMOD ALFA-FCAB
EFALIZUMAB vs EFGARTIGIMOD ALFA\HYALURONIDASE-QVFC
EFALIZUMAB vs EFINACONAZOLE
Official FDA Label for EFALIZUMAB
Official prescribing information from the FDA-approved drug label.